Obstet Gynecol. 2018 Jul;132(1):243-248. doi: 10.1097/AOG.0000000000002707.
Women who are pregnant or in the postpartum period have a fourfold to fivefold increased risk of thromboembolism compared with nonpregnant women (1, 2). Approximately 80% of thromboembolic events in pregnancy are venous (3), with a prevalence of 0.5-2.0 per 1,000 pregnant women (4-9). Venous thromboembolism (VTE) is one of the leading causes of maternal mortality in the United States, accounting for 9.3% of all maternal deaths (10).The prevalence and severity of this condition during pregnancy and the peripartum period warrant special consideration of management and therapy. Such therapy includes the treatment of acute thrombotic events and prophylaxis for those at increased risk of thrombotic events. The purpose of this document is to provide information regarding the risk factors, diagnosis, management, and prevention of thromboembolism, particularly VTE in pregnancy. This Practice Bulletin has been revised to reflect updated guidance regarding screening for thromboembolism risk and management of anticoagulation around the time of delivery.
与非孕妇相比，孕妇或产后妇女发生血栓栓塞的风险增加了四到五倍（1,2）。妊娠期间约有 80%的血栓栓塞事件为静脉血栓（3），每 1000 名孕妇中有 0.5-2.0 例（4-9）。静脉血栓栓塞症（VTE）是美国孕产妇死亡的主要原因之一，占所有孕产妇死亡的 9.3%（10）。妊娠和围产期期间这种疾病的发生率和严重程度需要特别考虑管理和治疗。这种治疗包括治疗急性血栓形成事件和预防那些有血栓形成事件风险增加的患者。本文件旨在提供有关血栓栓塞症风险因素、诊断、管理和预防的信息，特别是妊娠期间的 VTE。本实践公告已修订，以反映有关血栓栓塞症风险筛查和分娩前后抗凝管理的最新指南。
